Previous studies have shown that treatment of GBM-TICs with BMP4 or BMP7 triggers Smad-mediated signaling, leading to the inhibition of cell proliferation, the induction of differentiation and a reduction of tumor formation in immunodeficient mice [4, 6, 7]. This evidence concerns the gene BMP7 and glioblastoma.